(2021) conducted a phase I trial combining Pembrolizumab, an anti PD-1 agent, with regional mesothelin-targeted CAR-T cell therapy against patients with malignant pleural disease, including metastatic breast, lung, and malignant pleural mesothelioma (MPM) (145). This evidence concerns the gene MSLN and malignant pleural mesothelioma.